Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer?

医学 结直肠癌 内科学 肿瘤科 贝伐单抗 阶段(地层学) 中性粒细胞与淋巴细胞比率 癌症 全身炎症 疾病 转移 炎症 化疗 淋巴细胞 生物 古生物学
作者
Sabrina Rossi,Michele Basso,Antonia Strippoli,Giovanni Schinzari,Ettore D’Argento,Mario Larocca,Alessandra Cassano,Carlo Barone
出处
期刊:Clinical Colorectal Cancer [Elsevier BV]
卷期号:16 (4): 264-274 被引量:95
标识
DOI:10.1016/j.clcc.2017.03.015
摘要

Systemic inflammation has been proved to play a crucial role in promoting cancer progression and metastasis in many cancer types, including colorectal cancer (CRC). The aim of the present review was to provide an overview of studies regarding the prognostic value of inflammation-based markers in patients with CRC. A literature search was performed for articles reporting the prognostic value of the Glasgow prognostic score (GPS), modified GPS (mGPS), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) in relation to CRC outcomes. In resectable early-stage CRC, high GPS scores seem significantly associated with cancer-specific survival. It has also been suggested that adjuvant chemotherapy for stage II CRC could improve cancer-specific survival in patients with high GPS scores. In patients with both resectable and unresectable metastatic CRC and a higher GPS score, all studies suggested poorer overall survival. In early-stage and resectable metastatic CRC, the NLR seemed related to overall survival; however, the data for disease-free survival were discordant. In metastatic disease, a possible correlation between a greater NLR and poorer response to bevacizumab has been suggested. Data concerning the prognostic and predictive role of the PLR and LMR in CRC are to date insufficient. In patients with unresectable metastatic disease, inflammation markers can be used to predict the chemotherapeutic outcome and monitor tumor progression. However, further prospective studies might lead to better risk stratification for patients eligible for curative surgery, thus, allowing the restriction of neoadjuvant and adjuvant therapy to patients with high-risk CRC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小明完成签到,获得积分10
刚刚
einuo发布了新的文献求助10
刚刚
SYLH应助111采纳,获得10
1秒前
hh发布了新的文献求助10
4秒前
羊羊完成签到,获得积分10
4秒前
卡卡罗特先森完成签到 ,获得积分10
5秒前
朽木完成签到 ,获得积分10
7秒前
7秒前
fanyueyue应助111采纳,获得10
9秒前
9秒前
9秒前
kcmat发布了新的文献求助10
10秒前
hh完成签到,获得积分10
11秒前
Philadelphus发布了新的文献求助10
12秒前
einuo完成签到,获得积分10
12秒前
AKYDXS完成签到,获得积分10
15秒前
昏睡的蟠桃应助Llllll采纳,获得200
15秒前
科研通AI2S应助hao采纳,获得10
15秒前
16秒前
16秒前
香蕉觅云应助阿湫采纳,获得10
17秒前
星辰大海应助星辰采纳,获得10
17秒前
阿卡宁完成签到,获得积分10
17秒前
lzw完成签到 ,获得积分10
17秒前
沉静烧仙草完成签到,获得积分20
18秒前
烟花应助嘉嘉琦采纳,获得10
18秒前
隐形曼青应助科研通管家采纳,获得10
18秒前
Hello应助科研通管家采纳,获得10
19秒前
Ava应助科研通管家采纳,获得10
19秒前
上官若男应助科研通管家采纳,获得10
19秒前
19秒前
赘婿应助科研通管家采纳,获得10
19秒前
烟花应助科研通管家采纳,获得10
19秒前
FashionBoy应助科研通管家采纳,获得10
19秒前
英俊的铭应助科研通管家采纳,获得10
19秒前
在水一方应助科研通管家采纳,获得10
19秒前
accepted应助科研通管家采纳,获得10
19秒前
脑洞疼应助科研通管家采纳,获得10
19秒前
19秒前
cdh1994应助kcmat采纳,获得10
19秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038524
求助须知:如何正确求助?哪些是违规求助? 3576221
关于积分的说明 11374737
捐赠科研通 3305912
什么是DOI,文献DOI怎么找? 1819354
邀请新用户注册赠送积分活动 892688
科研通“疑难数据库(出版商)”最低求助积分说明 815048